Rigel Pharmaceuticals Inc. (New) (RIGL) Dividend History

Rigel Pharmaceuticals Inc. (RIGL) is a biotechnology company focused on discovering and developing targeted therapies for underserved disease areas, primarily in immunology, oncology, and rare diseases. Founded in 1997, the company leverages its expertise in kinase inhibition and intracellular signaling to develop innovative medications aimed at improving patient outcomes. Rigel's portfolio includes both approved drugs and promising clinical-stage candidates.

611 Gateway Boulevard, Suite 900, South San Francisco, CA, 94080
Phone: 650-624-1100
Website: https://www.rigel.com

Dividend History

Rigel Pharmaceuticals Inc. (New) currently does not pay dividends

Company News

Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® au Mexique

Knight Therapeutics, a specialty pharmaceutical company, announced that its Mexican subsidiary has obtained regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) whose response to prior treatment was insufficient.

GlobeNewswire Inc.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals

The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

GlobeNewswire Inc.

Featured Companies: CRVS
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates

Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research

Featured Companies: MEIP
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

Featured Companies: PRPH

Dividend data last updated 06/07/2025 10:01:49 UTC